OUTCOMES IN TREATMENT OF EUROPEAN (EU) PATIENTS WITH COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (CABP) COMPARING DELAFLOXACIN (DLX) AND MOXIFLOXACIN (MOX) | Publicación